JFGIW
VKTX icon

Johnson Financial Group Inc (Wisconsin)’s Viking Therapeutics VKTX Stock Holding History

Johnson Financial Group Inc (Wisconsin)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-924
Closed -$24.3K – 1115
2025
Q3 		$24.3K Buy
+924
New +$27.6K ﹤0.01% 698

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Johnson Financial Group Inc (Wisconsin)'s VKTX Position: Q4 2025 in Review

Johnson Financial Group Inc (Wisconsin) sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 924 shares — an estimated $24.3K sold.

Johnson Financial Group Inc (Wisconsin) first reported a position in VKTX in Q3 2025 and held it in 1 quarter. The position peaked at $24.3K in Q3 2025. 424 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • Johnson Financial Group Inc (Wisconsin) reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Johnson Financial Group Inc (Wisconsin) sold 924 Viking Therapeutics shares in Q4 2025, an estimated $24.3K.
  • Johnson Financial Group Inc (Wisconsin) first reported a position in Viking Therapeutics in Q3 2025 and held it in 1 quarter.
  • Johnson Financial Group Inc (Wisconsin)'s Viking Therapeutics position peaked at $24.3K in Q3 2025.
  • 424 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Johnson Financial Group Inc (Wisconsin)'s 13F filing for Q4 2025, filed 12 Feb 2026.